GlassScriptPhysician profile
Marni J Friedman
NPI 1477647121
$13,012.06
in general payments reported to CMS, 2019-2025
42 companies · $1,655 in 2025
The $1,655 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,575 · 2020: $1,693 · 2021: $2,751 · 2022: $2,208 · 2023: $1,324 · 2024: $1,807 · 2025: $1,655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,588 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,588.02 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,809.88 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,627.43 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,560.07 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,530.22 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $965.94 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $683.59 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $487.01 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $405.92 | 2020-2023 | |
| Sanofi-Aventis U.S. LLC | $350.52 | 2019-2023 | |
| Lilly USA, LLC | $325.30 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $305.59 | 2019-2024 | Repatha, Otezla |
| Pfizer INC. | $295.79 | 2023-2025 | |
| Abbott Laboratories | $254.70 | 2022-2024 | Freestyle Libre 3 |
| Allergan, INC. | $182.55 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $173.25 | 2023-2025 | Caplyta |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $151.62 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $132.48 | 2022 | |
| Boston Scientific Corporation | $124.50 | 2021 | |
| Heartflow, INC. | $120.30 | 2024 | |
| Axsome Therapeutics, INC. | $117.21 | 2025 | Auvelity |
| Medtronic, INC. | $116.49 | 2023 | Eea |
| Janssen Biotech, INC. | $113.20 | 2025 | Tremfya, Simponi Aria, Simponi |
| Exact Sciences Corporation | $111.32 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceuticals, INC. | $110.39 | 2021 | |
| Alnylam Pharmaceuticals INC. | $109.31 | 2022 | |
| Sunovion Pharmaceuticals INC. | $104.16 | 2021-2022 | |
| Amarin Pharma, INC. | $100.35 | 2019 | |
| Astellas Pharma US INC | $99.00 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $94.52 | 2019-2022 | |
| Dexcom, INC. | $94.08 | 2022-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $81.68 | 2020-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $50.98 | 2021-2023 | Trintellix |
| Indivior INC. | $46.24 | 2025 | Sublocade |
| Organon LLC | $28.90 | 2023 | Nexplanon |
| Philips North America LLC | $26.87 | 2021 | |
| Medtronic Vascular, INC. | $19.71 | 2020 | |
| Esperion Therapeutics, INC. | $19.43 | 2022 | |
| Alkermes, INC. | $18.79 | 2025 | Aristada, Lybalvi |
| Scilex Pharmaceuticals INC. | $18.66 | 2024 | |
| Zyla Life Sciences, INC. | $15.31 | 2020 | |
| Avanir Pharmaceuticals, INC. | $15.00 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.80 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marni Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.